ONCSQ Stock - OncoSec Medical Incorporated
Unlock GoAI Insights for ONCSQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,066,316 | $-1,078,163 | $-990,288 | $-243,712 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-37,012,062 | $-48,380,058 | $-43,409,085 | $-30,416,678 | $-36,105,359 |
| Net Income | $-34,179,634 | $-45,167,731 | $-42,253,426 | $-30,276,053 | $-39,136,366 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-19.13 | $-30.20 | $-56.22 | $-94.43 | $-214.59 |
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.
Visit WebsiteEarnings History & Surprises
ONCSQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Oct 25, 2024 | — | — | — | — |
Q2 2024 | Jun 12, 2024 | — | — | — | — |
Q1 2024 | Mar 13, 2024 | — | — | — | — |
Q4 2023 | Dec 8, 2023 | — | — | — | — |
Q4 2023 | Oct 27, 2023 | $-17.17 | — | — | — |
Q2 2023 | Jun 15, 2023 | $-16.98 | — | — | — |
Q1 2023 | Jan 31, 2023 | $-28.90 | $-2.65 | +90.8% | ✓ BEAT |
Q4 2022 | Oct 31, 2022 | $-107.77 | $-4.50 | +95.8% | ✓ BEAT |
Q3 2022 | Jul 31, 2022 | $-4.62 | $-4.59 | +0.6% | ✓ BEAT |
Q2 2022 | Apr 30, 2022 | $-3.52 | $-3.49 | +0.8% | ✓ BEAT |
Q1 2022 | Jan 31, 2022 | $-3.96 | $-5.54 | -40.0% | ✗ MISS |
Q4 2021 | Oct 31, 2021 | — | $-5.51 | — | — |
Q3 2021 | Jul 31, 2021 | $-8.20 | $-6.65 | +18.9% | ✓ BEAT |
Q2 2021 | Apr 30, 2021 | — | $-5.56 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-8.21 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-10.87 | — | — |
Q3 2020 | Jul 31, 2020 | — | $-8.58 | — | — |
Q2 2020 | Apr 30, 2020 | — | $-9.91 | — | — |
Q1 2020 | Jan 31, 2020 | — | $-28.00 | — | — |
Q4 2019 | Oct 31, 2019 | — | $-20.17 | — | — |
Latest News
Frequently Asked Questions about ONCSQ
What is ONCSQ's current stock price?
What is the analyst price target for ONCSQ?
What sector is OncoSec Medical Incorporated in?
What is ONCSQ's market cap?
Does ONCSQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ONCSQ for comparison